Sep 26, 2023 6:00 am EDT Immunovant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results
Sep 25, 2023 11:01 pm EDT Immunovant to Host Conference Call and Webcast to Report Initial IMVT-1402 Phase 1 Results on September 26, 2023
Aug 10, 2023 7:00 am EDT Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2023
May 22, 2023 7:00 am EDT Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023
Feb 03, 2023 7:00 am EST Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended December 31, 2022
Nov 07, 2022 8:00 am EST Immunovant to Present at Guggenheim 4th Annual Immunology and Neurology Day on November 14th
Nov 04, 2022 7:00 am EDT Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended September 30, 2022
Oct 04, 2022 8:45 am EDT Immunovant Announces Pricing of $75.0 Million Underwritten Offering of Common Stock